What is your treatment approach for patients with an IDH wild-type, low-grade glioma?

Given the poor prognosis of molecular subtype, do you offer a more aggressive treatment regimen than for other molecular subtypes of low-grade glioma?

Answer from: Radiation Oncologist at Academic Institution

Our neuro-oncology group has begun using concurrent and adjuvant TMZ for patients with IDH wildtype. Our radonc group supports doses of 54 to 60Gy, favoring use of 60Gy on institutional protocol in order to assess the long-term outcomes.

Comments

Radiation Oncologist at Radiant Oncology
For patients with poor performance status, would y...

Answer from: Radiation Oncologist at Community Practice

Timely ASCO abstract from NRG/RTOG 9802: http://abstracts.asco.org/239/AbstView_239_252343.html Wild type did not seem to benefit from PCV, but TMZ not evaluated.

Please select the option that best describes you:

What is your treatment approach for patients with an IDH wild-type, low-grade glioma?

Related Questions